Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | ABCB1 | P08183 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16072779 | 1.00 | GAA (0.39) | GAATSHRABCB1KMT2ACHRM2 | |
| SCHEMBL9687625 | 0.89 | GAA (0.37) | GAATSHRCHRM2CHRM4CHRM1 | |
| SCHEMBL16077026 | 0.87 | RAB9A (0.46) | GAATSHRABCB1KMT2ACHRM2 | |
| SCHEMBL16155139 | 0.87 | RAB9A (0.46) | GAATSHRABCB1KMT2ACHRM2 | |
| SCHEMBL16072769 | 0.87 | RAB9A (0.46) | GAATSHRABCB1KMT2ACHRM2 | |
| SCHEMBL1584062 | 0.79 | GAA (0.52) | GAATSHRKMT2AAPOBEC3AAPOBEC3G | |
| SCHEMBL16077036 | 0.77 | BCHE (0.31) | BCHE | |
| SCHEMBL10729081 | 0.77 | RAB9A (0.48) | GAATSHRABCB1KMT2ACHRM2 | |
| SCHEMBL16077037 | 0.77 | BCHE (0.31) | BCHE | |
| SCHEMBL16077032 | 0.77 | BCHE (0.31) | BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345678-B2 | Prostanoid receptor agonist compounds and methods of use for same | ALLERGAN, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| WO-2014164886-A1 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND THEIR USE | ALLERGAN, INC. (US) | 2014-10-09 | — | — | WO | disclosed |
| US-20140275266-A1 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275266-A1 | PROSTANOID RECEPTOR AGONIST COMPOUNDS AND METHODS OF USE FOR SAME | PTGIR, PTGER1, PTGDR | GAA 3940/4885TSHR 879/4885ABCB1 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.